Genelux Corp. (GNLX) AI Stock Analysis

• Market Cap: $122.53M
• Dividend Yield: N/A
• Average Volume (3M): 156.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: -100.00%
• EPS Growth: 7.80%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 44,718,437
• 10 Day Avg. Volume: 178,540
• 30 Day Avg. Volume: 156,945
• PEG Ratio: 0.14
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 9277.96
• P/FCF Ratio: -3.43
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -577.90
• Enterprise Value/Ebitda: -2.62
• 1Y Price Target: $22.50
• Price Target Upside: 721.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $3.50 ▲(27.74% Upside)

The score is held down primarily by negligible revenue with large ongoing losses and heavy cash burn, alongside bearish technicals with the stock trading below key moving averages. Positive corporate developments (early trial signals, leadership hire, and added financing capacity) help, but are not enough to outweigh current financial weakness and dilution risk.

Positive Factors

Promising Olvi-Vec clinical signals

Systemic Olvi-Vec showing objective responses and disease control in relapsed lung cancer provides structural clinical proof-of-concept for the platform. Durable systemic activity can de-risk development, support expanded indications, enable pivotal program planning, and improve partner and investor interest over months.

Experienced clinical leadership

Hiring a seasoned CMO with deep oncology development experience strengthens trial design, regulatory strategy, and translational decision-making. This raises execution quality, accelerates pathway to pivotal studies, and materially improves long-term probability of successful registrations and collaborations.

Low leverage and positive equity

A modest debt load and positive equity provide structural balance-sheet stability compared with higher-leverage peers. Lower interest burden and cleaner capital structure reduce refinancing stress, giving management more flexibility to prioritize clinical milestones and partnership strategies over short-term debt servicing.

Negative Factors

High and persistent cash burn

Sustained negative operating and free cash flow indicates material runway consumption from operations. Over 2–6 months this necessitates new financing or partner deals, elevating execution risk for clinical programs and increasing the chance of program delays or scope reductions if capital access tightens.

No material product revenue; sustained losses

As a clinical-stage biotech with negligible revenue and recurring large net losses, the company remains structurally dependent on external funding. Continued negative profitability limits reinvestment from operations and heightens dilution and program-risk if clinical readouts do not materially de-risk the pipeline.

Ongoing equity raises and dilution risk

Frequent reliance on public equity offerings to fund operations creates structural dilution risk and ties execution to access to capital markets. Over the medium term, this can reduce existing shareholder value, complicate long-term incentives, and pressure management to prioritize financing cadence alongside development milestones.

Genelux Corp. Business Overview & Revenue Model

Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

How the Company Makes Money

Genelux Corp. generates revenue through several key streams, primarily focused on the development and commercialization of its oncolytic virus therapies. The company earns money by conducting clinical trials and securing partnerships with pharmaceutical companies for co-development and licensing agreements. These collaborations may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory events, and royalties on future sales of successful products. Additionally, Genelux may benefit from government grants and funding aimed at supporting innovative cancer research, which can contribute to its overall financial health. The success of its pipeline products and strategic partnerships play a crucial role in the company's revenue generation.

Genelux Corp. Financial Statement Overview

Summary

Genelux Corp. is facing significant financial challenges, with persistent negative profitability and cash flow issues. Despite some improvements in equity, the company remains highly leveraged. The dependency on financing activities for cash flow sustainability is risky, especially given the volatile nature of the biotechnology industry.

Income Statement

Genelux Corp. shows weak profitability with consistently negative net incomes over the years. The 2024 revenue growth is misleading due to the low base effect from previous years. Gross profit margin is positive due to costs being reported as negative, but net profit margin remains negative, indicating ongoing operational challenges. Both EBIT and EBITDA margins are negative, underscoring significant profitability issues.

Balance Sheet

The company has improved its equity position, transitioning from negative to positive stockholders' equity in recent years, which is a positive sign. However, the debt-to-equity ratio improved but remains concerning, reflecting high leverage. The equity ratio indicates a low percentage of assets financed by equity, limiting financial flexibility.

Cash Flow

Operating cash flows remain negative, indicating ongoing operational losses. Free cash flow is also negative, with no clear growth trajectory. The operating cash flow to net income ratio is not favorable, reflecting inefficiencies in converting income into cash. Financing activities are primarily sustaining the cash position, which poses risks if external financing becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	8.00K	170.00K	11.07M	0.00	0.00
Gross Profit	-143.00K	-895.00K	-848.00K	10.10M	-895.00K	-658.00K
EBITDA	-31.55M	-28.97M	-26.46M	-1.73M	-13.67M	-11.76M
Net Income	-31.87M	-29.87M	-28.30M	-5.21M	-17.80M	-14.86M
Balance Sheet
Total Assets	24.99M	34.72M	27.89M	5.53M	8.13M	14.01M
Cash, Cash Equivalents and Short-Term Investments	20.91M	30.89M	23.19M	397.00K	4.50M	11.35M
Total Debt	1.62M	1.87M	2.52M	26.35M	25.31M	26.06M
Total Liabilities	6.40M	8.44M	8.42M	41.31M	41.24M	36.66M
Stockholders Equity	18.59M	26.27M	19.47M	-35.78M	-33.11M	-22.66M
Cash Flow
Free Cash Flow	-24.13M	-21.61M	-21.30M	-3.62M	-6.58M	-7.22M
Operating Cash Flow	-23.37M	-21.23M	-20.27M	-3.57M	-6.58M	-7.21M
Investing Cash Flow	12.25M	-8.13M	-14.72M	-49.00K	0.00	-20.00K
Financing Cash Flow	9.71M	28.51M	44.02M	-478.00K	-270.00K	18.15M

Genelux Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Negative. The current price of 2.74 is below the 20-day moving average (MA) of 3.63, below the 50-day MA of 4.49, and below the 200-day MA of 3.84, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 28.73 is Positive, neither overbought nor oversold. The STOCH value of 7.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNLX.

Genelux Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FBRX	56 Neutral	$418.27M	-7.51	-110.72%	―	―	77.08%
CHRS	52 Neutral	$193.39M	-1.01	―	―	-72.54%	-19972.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBP	49 Neutral	$146.04M	-1.51	-55.65%	―	―	-17.43%
FATE	47 Neutral	$137.27M	-0.90	-52.35%	―	-46.92%	20.26%
GNLX	44 Neutral	$122.53M	-3.12	-98.72%	―	-100.00%	7.80%
TNXP	43 Neutral	$219.19M	-0.02	-64.99%	―	-8.79%	81.36%

Genelux Corp. Corporate Events

Genelux Announces Underwritten Public Offering to Raise Capital

On January 8, 2026, Genelux Corporation entered into an underwriting agreement with Lucid Capital Markets to conduct an underwritten public offering of 6,666,667 shares of its common stock at $3.00 per share, all sold by the company, for expected gross proceeds of about $20 million before fees, with closing anticipated on January 9, 2026 subject to customary conditions. The equity raise, launched via press announcements on January 7 and January 8, 2026 under an effective shelf registration, reinforces Genelux’s access to capital markets and is expected to provide additional funding flexibility as it advances its late-stage immuno-oncology pipeline, with terms that include standard representations, indemnification provisions and an option for the underwriter to purchase additional shares.

The most recent analyst rating on (GNLX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.

Genelux Reports Encouraging Interim Data for Olvi-Vec Trials

On January 5, 2026, Genelux Corporation reported interim data from two ongoing trials of its oncolytic immunotherapy Olvi-Vec given intravenously to patients with progressive small cell and non-small cell lung cancer whose disease had relapsed or progressed after prior platinum-based regimens, showing preliminary signs of anti-tumor activity and tolerability. In the China-based Phase 1b/2 SCLC study, as of December 23, 2025, Olvi-Vec in combination with platinum and etoposide produced a 33% overall response rate and 67% disease control rate among nine evaluable patients, with notable tumor shrinkage in the highest-dose cohort and early signals of durable progression-free survival despite the trial’s primary focus on safety. In the U.S.-based Phase 2 VIRO-25 NSCLC trial, as of December 31, 2025, five evaluable patients treated with Olvi-Vec plus platinum chemotherapy and an immune checkpoint inhibitor achieved a 60% disease control rate with generally manageable safety. These early findings suggest potential for systemically delivered Olvi-Vec to resensitize difficult-to-treat lung tumors to platinum therapy and support Genelux’s broader strategy to position Olvi-Vec as a differentiated immunotherapy across multiple solid tumors, with further lung cancer readouts and pivotal ovarian cancer data expected to shape the company’s clinical and regulatory trajectory in 2026.

The most recent analyst rating on (GNLX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.

Genelux Appoints Veteran Oncologist Jason Litten as CMO

On December 30, 2025, Genelux Corporation’s Chief Medical Officer, Paul Scigalla, M.D., resigned effective immediately, and on January 2, 2026, the company appointed oncology specialist Jason Litten, M.D., as its new Chief Medical Officer. Litten, a veteran of Chimeric Therapeutics, Artiva Biotherapeutics, Juno Therapeutics, Clovis Oncology and Amgen, brings extensive experience in developing CAR-T, TCR, NK cell therapies and other cancer medicines; his compensation package includes a $475,000 base salary, performance-based bonus eligibility, equity incentives with change-in-control acceleration, and severance protections, underscoring Genelux’s effort to strengthen its clinical leadership and retain key talent during potential corporate transitions.

The most recent analyst rating on (GNLX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.